UCB’s 9M 17 results (trading update) came in ahead of both ours and the Street’s expectations. Top-line grew strongly at 9% CER (9% reported as the 2ppt HY 17 currency tailwinds reversed in the quarter) to €3.33bn (c.3% ahead of consensus estimate of €3.24bn), driven by a sustained performance across the CVN portfolio, in particular, Vimpat (+20%). This was supported further by strong returns from the off-patent drug Keppra (+14%, driven by stocking benefits, Japan and i
25 Oct 2017
Consensus beat; focus on pipeline delivery
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Consensus beat; focus on pipeline delivery
UCB S.A. (UCB:WBO) | 0 0 1.1% | Mkt Cap: 13,141m
- Published:
25 Oct 2017 -
Author:
Jyoti Prakash -
Pages:
4
UCB’s 9M 17 results (trading update) came in ahead of both ours and the Street’s expectations. Top-line grew strongly at 9% CER (9% reported as the 2ppt HY 17 currency tailwinds reversed in the quarter) to €3.33bn (c.3% ahead of consensus estimate of €3.24bn), driven by a sustained performance across the CVN portfolio, in particular, Vimpat (+20%). This was supported further by strong returns from the off-patent drug Keppra (+14%, driven by stocking benefits, Japan and i